NBSC New Brunswick Scient (MM)

EDISON, N.J., Oct. 3 /PRNewswire-FirstCall/ -- New Brunswick Scientific Co., Inc. (NBS) (NASDAQ:NBSC), today announced the roll-out of FibraStage(TM), a new disposable cell culture system in the Company's extensive range of equipment for culture growth, detection and storage. According to New Brunswick Scientific President and Chief Operating Officer James Orcutt, the FibraStage system provides all of the advantages of existing pre-sterilized, single-use cell culture systems -- eliminating the need for cleaning and autoclaving -- while at the same time offering reduced operating cost, compact size and high yields of protein, virus or cell mass from anchorage-dependent or suspension cultures. Orcutt explained, "At the heart of the FibraStage system is a console base that accommodates up to four 500 ml disposable culture vessels pre-filled with patented FibraCel(R) disks. FibraCel is a solid-support matrix designed to provide an increased surface area for cell growth, resulting in higher cell densities. A single FibraStage system can eliminate the need to maintain numerous spinner flasks, dozens of roller bottles and hundreds of T-flasks." "Thus far in 2005, we have launched several innovative new products including two biological shakers and the FibraStage system. We look forward to the roll-out of additional products and product enhancements during the year's final quarter and continuing throughout 2006," Orcutt concluded. Applications for the FibraStage cell culture system include virus and vaccine production, gene therapy/drug discovery, human proteome, and cell therapy and tissue engineering. To be added to New Brunswick Scientific's e-mail distribution list, please click on the link below: http://www.clearperspectivegroup.com/clearsite/nbsc/emailoptin.html About New Brunswick Scientific New Brunswick Scientific Co., Inc., is a leading global provider of a comprehensive line of research equipment and scientific instrumentation for use in the life science industry. The Company's products are used in the creation, maintenance and control of physical and biochemical environments required for the growth, detection and storage of microorganisms for medical, biological and chemical applications, as well as environmental research and commercial product development. NBS is a forerunner in the research and development of pioneering equipment to meet the challenges of new areas of advancement in life science. Established in 1946, New Brunswick Scientific is headquartered in Edison, New Jersey, with sales and distribution facilities strategically located in the United States, Europe and Asia. For more information, please visit http://www.nbsc.com/ . This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements may be identified by words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "will" or words of similar meaning and include, but are not limited to, statements about the expected future business and financial performance of the Company. The forward-looking statements involve a number of risks and uncertainties, including but not limited to, changes in economic conditions, demand for the Company's products, pricing pressures, intense competition in the industries in which the Company operates, the need for the Company to keep pace with technological developments and respond in a timely manner to changes in customer needs, the Company's dependence on third-party suppliers, the effect on foreign sales of currency fluctuations, acceptance of new products, the labor relations of the Company and its customers and other factors identified in the Company's Securities and Exchange Commission filings. Forward-looking statements are based on management's current expectations and assumptions, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict. Actual outcomes and results may differ materially from these expectations and assumptions due to changes in global political, economic, business, competitive, market, regulatory and other factors. The Company undertakes no obligation to publicly update or review any forward-looking information, whether as a result of new information, future developments or otherwise. DATASOURCE: New Brunswick Scientific Co., Inc. CONTACT: Investors: Samuel Eichenbaum, Vice President, Finance and Treasurer of New Brunswick Scientific Co., Inc., +1-732-650-2500, ; or Matthew J. Dennis, CFA, NBS Investor Relations, Clear Perspective Group, LLC, +1-440-353-0552, Web site: http://www.nbsc.com/

Copyright